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Background: Breast cancer is the most common female cancer worldwide. The lifetime risk of a woman being
diagnosed with breast cancer is approximately 12.5%. For women who carry the deleterious mutation in either of the
BRCA genes, BRCA1 or BRCA2, the risk of developing breast or ovarian cancer is significantly increased. In recent years
there has been increased penetrance of BRCA1 and BRCA2 associated breast cancer, prompting investigation into the
role of modifiable risk factors in this group. Previous investigations into this topic have relied on participants recalling
lifetime weight changes and subjective methods of recording physical activity. The influence of obesity-related
biomarkers, which may explain the link between obesity, physical activity and breast cancer risk, has not been
investigated prospectively in this group. This paper describes the design of a prospective cohort study investigating the
role of predictive and modifiable risk factors for breast cancer in unaffected BRCA1 and BRCA2 gene mutation carriers.
Methods/design: Participants will be recruited from breast cancer family risk clinics and genetics clinics. Lifestyle risk
factors that will be investigated will include body composition, metabolic syndrome and its components, physical
activity and dietary intake. PBMC telomere length will be measured as a potential predictor of breast cancer
occurrence. Measurements will be completed on entry to the study and repeated at two years and five years.
Participants will also be followed annually by questionnaire to track changes in risk factor status and to record cancer
occurrence. Data will be analysed using multiple regression models. The study has an accrual target of 352 participants.
Discussion: The results from this study will provide valuable information regarding the role of modifiable lifestyle risk
factors for breast cancer in women with a deleterious mutation in the BRCA gene. Additionally, the study will attempt
to identify potential blood biomarkers which may be predictive of breast cancer occurrence.
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Telomere lengthBackground
Breast cancer is the most common female malignancy
worldwide. The lifetime risk of a woman being diagnosed
with breast cancer is approximately 12.5% [1]. While most
breast cancers are sporadic in nature, approximately 5-
10% are attributed to genetics, arising from autosomal
dominant mutations in specific cancer genes, the strongest
of which are the two breast cancer susceptibility genes,* Correspondence: emguinan@tcd.ie
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reproduction in any medium, provided the orBRCA1 or BRCA2. Women who carry these mutations
have up to an 80% risk of developing breast and up to a
60% risk of ovarian cancer [2-4]. In recent years, there has
been increased penetrance of BRCA1/2 mutations, which
is most likely mediated by lifestyle or environmental
influences [2,5,6], prompting investigation into the poten-
tial of reducing risk through lifestyle modification in this
group. Understanding how modifiable and lifestyle risk
factors affect cancer risk, specifically in BRCA mutation
carriers, may have important implications for cancer
prevention in this high risk group.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and certain components of dietary intake such as alcohol
consumption and sporadic breast cancer risk are well
established [7-10]. Obesity may increase breast cancer
risk through a number of different mechanisms including
insulin resistance, the metabolic syndrome, increased
production of sex hormones, insulin-like growth factors,
chronic low-grade inflammation and alterations in
adipokines[9,11-15]. These biological pathways, in turn,
are the hypothesised targets through which physical activity
may exert its protective effects over breast cancer
development [16,17]. However, knowledge regarding the
role of these lifestyle factors in BRCA1/2 mutation carriers
is limited.
A number of case-control studies have investigated the
association between adult weight change and breast
cancer risk in BRCA gene mutation carriers through
self-reported recall of lifetime weight changes [2,18-20].
Healthy weight during adult life, particularly from
menarche to 21 years, has been associated with decreased
breast cancer risk [18,20] while weight loss between 18
and 30 years of age has been associated 34% reduction in
breast cancer risk, particular among BRCA1 mutation
carriers [18]. Consistent with sporadic breast cancer,
menopausal status is a potentially modifying factor in
the relationship between obesity and breast cancer risk in
BRCA mutation carriers, however results are conflicting.
A study by Kotsopoulos and colleagues [18], reported
increased breast cancer risk with adult weight gain,
regardless of menopausal status, while Manders et al.,
[19] reported an association with postmenopausal breast
cancer only. However, in these studies, body weight has
been self-reported, rather than objectively measured,
leading to potential inaccuracies in results. The association
between physical activity and BRCA mutation-associated
breast cancer is unclear with two studies reporting a
protective effect [2,21] and one showing no association
[20]. However, as with the anthropometric variables,
measurement methods were limited and relied on
self-reported recall.
In addition, it has been suggested that measuring
telomere length may help predict risk of occurrence of
certain types of cancer [22-24] including BRCA mutation-
associated breast cancer [25,26]. There is some evidence
to suggest that exercise may affect telomere length. For
example, Puterman et al, showed that increased perceived
stress was associated with increased odds of having short
telomeres but only in non-exercising women [27].
Non-exercising women with a history of childhood abuse
had shorter telomeres than those with no history of abuse;
however, in women who exercised regularly no link
between childhood abuse and telomere length was found
[28]. Together, these findings suggest that telomere
shortening may be modifiable by physical activity.Reproductive factors including parity and breastfeeding
practices have been associated with risk reduction in
BRCA mutation carriers similar to that of the general
population [29,30], suggesting that modifiable risk factors
can attenuate risk in this group. However, our under-
standing of the potential for risk reduction for the majority
of modifiable of risk factors in this high risk group
remains unknown. Studies investigating women with a
strong family history of breast cancer have shown that
these women are no more likely to engage in healthy
lifestyle habits than women in the general population
[31,32] making lifestyle interventions a potentially import-
ant target. The Consortium of Investigators of Modifiers
of BRCA1/2 (CIMBA) is currently examining the role of
various genetic modifiers of cancer risk in BRCA mutation
carriers. Within CIMBA, and as part of the Epidemiological
Study of Familial Breast Cancer (EMBRACE) study and
others, the influence of lifestyle factors on breast cancer
occurrence will be measured subjectively using a lifestyle
questionnaire (http://ccge.medschl.cam.ac.uk/embrace/).
However these associations have not been investigated
using validated and objective measures of lifestyle
parameters.
We plan to prospectively and objectively examine the
association between modifiable (body composition,
metabolic syndrome, physical activity and dietary intake)
and potentially predictive (telomere length) risk factors for
breast cancer and breast cancer occurrence in unaffected
BRCA1 and BRCA2 gene mutation carriers. This study
will also investigate the hypothesised link between phys-
ical activity and telomere length in a cohort of un-
affected BRCA-mutation carriers. Various correlations
between telomere length and physical activity, lifestyle fac-
tors and breast cancer occurrence will be examined.
Methods / design
Study design
This study is designed as a prospective cohort study aiming
to evaluate the role of modifiable and predictive risk factors
for breast cancer in women who have been genetically
tested and identified as carriers of a deleterious mutation in
either one of the BRCA genes, BRCA1 or BRCA2.
Objectives
1. To determine information on metabolic syndrome,
body composition, physical activity, diet, telomere
length and hormone measurements from women
who are unaffected BRCA1/2 mutation carriers.
2. To assess the associations between the following
with body composition, physical activity and dietary
intake in unaffected BRCA1/2 mutation carriers:
 Insulin resistance
 Leptin




3. To prospectively examine the relationship
between the metabolic syndrome, body
composition, physical activity, diet, telomere
length, and hormone measurements with breast
cancer occurrence among BRCA1/2 mutation
carriers.
Participant recruitment
A convenience sample of BRCA gene mutation carriers
will be recruited from St. James’s Hospital, Dublin and
the National Centre for Medical Genetics, Our Lady’s
Children’s Hospital, Crumlin, Dublin. Potentially suit-
able participants, who have previously undergone gen-
etic testing and have been identified as carriers of
either the BRCA1 or BRCA2 mutation, will be identi-
fied at Breast Cancer Family Risk clinics and Cancer Gen-
etics clinics, by medical teams and specialised breast
cancer and medical nurses. At the St. James’s Hospital site,
potentially suitable participants will be provided with in-
formation leaflets about the study during routine med-
ical consultations, and if interested in gaining further
information, will be directed to speak to a member of
the research team who will attend the clinic. At the Na-
tional Centre for Medical Genetics, Our Lady’s Children’s
Hospital, Crumlin potentially suitable participants will be
provided with information leaflets detailing the study dur-
ing medical appointments and invited to contact the re-
search team by email or by telephone if interested in
gaining further information. Study personnel will pro-
vide further information to interested participants and
assess for eligibility. Ethical approval has been granted
by the SJH/AMNCH Joint Hospital Research Ethics
Committee, in accordance with the Helsinki declar-
ation, and written informed consent will be obtained
from all participants.
Participants who meet the following criteria will be
eligible to participate:
i. Women who have been genetically tested and
identified as carriers of a deleterious mutation in
either one of a BRCA genes, BRCA1/2 and who
do not have a history or either breast or ovarian
cancer.
ii. Aged 18 years or above
iii. Able to understand English.
iv. Willing to travel to the study site for measurements.
Participants will be excluded for the following reasons:
i. History of cancer or evidence of active disease
(exception: non-melanoma skin cancer).ii. Confirmed pregnancy or history of childbirth in
the preceding 6 months. Women who become
pregnant during the study period will complete
follow-up active assessments at least 6 months
after giving birth.
iii. Any medical co-morbidity that would preclude the
ability to participate in the study
iv. Dependence on a mobility assistive device.
v. Participants, who at the local investigator’s
discretion are not thought appropriate e.g. very
upset and emotional regarding finding of BRCA gene
mutation, family, work or transport issues that
would make participation difficult.
Assessments
Participants will complete three active assessments during
the study (baseline/entry to the study, two-years, and
five-years) during which all measurements outlined below
will be completed. Information on disease occurrence, risk
reducing procedures and current lifestyle habits will be
gathered yearly for 10 years using posted questionnaires.
The flow of data collection throughout the study is shown
in Figure 1.
Baseline characteristics
Demographic details will be gathered from medical
charts and through patient interview. Details on past
medical history, breast cancer risk factors (family history
of breast cancer, oral contraceptive use, age at first birth,
menopausal status, parity), and socio-demographic
variables including smoking history, alcohol habits,
employment status and marital status will be collected.
Body composition
Anthropometric data will be collected following a 12 hour
fast. Standing height will be measured, without shoes, to
the nearest millimetre using SECA stadiometer. Body
composition will be estimated using a bioimpedance
analyser, the Tanita MC 180 MA Multi-Frequency Body
Composition Analyzer (Tanita Corp, Tokyo, Japan).
Data output from the Tanita will be recorded and will
include body weight, body mass index (BMI), percentage
body fat, muscle mass and fat free mass. Waist circumfer-
ence will be measured using a flexible measuring tape,
in duplicate, to the nearest millimetre, at the mid-
point between the top of the iliac crest and the last
rib [33]. Lifetime weight changes will be assessed at the
initial assessment by asking participants to recall their
birth weight, weight at menarche, weight at age 18, 21, 30
and 40 respectively.
Blood pressure
Resting blood pressure will be measured using the
auscultatory method in accordance with the Joint National
Participants will be followed for 10 year. Breast cancer occurrence will be recorded. Data will be 
analysed for associations between modifiable lifestyle risk factors for breast cancer and breast 
cancer occurrence. 
Assessment 2: Two Years
Body composition, metabolic syndrome, physical activity and dietary intake will be measured.
Annual Questionnaire
Changes in lifestlye risk factors will be recorded annually using postal questionnaires. 
Baseline Assessment
Body composition, metabolic syndrome, physical activity and dietary intake measured. PBMC's 
will be isolated and DNA will be extracted from these samples.
Changes in lifestyle risk factors will be recorded annually using postal questionnaires. 
Annual Questionnaire
Changes in lifestyle risk factors will be recorded annually using postal questionnaires.  
Assessment 3: Five Years
Body composition, metabolic syndrome, physical activity and dietary intake will be measured.  
Annual Questionnaire
Figure 1 Flow of data collection throughout the study. Active assessments will be completed at baseline, two years and five years. Annual
questionnaires will be sent by post to participants following enrolment to monitor change in lifestyle risk factors being measured.
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Treatment of High Blood Pressure guidelines [34].
Measurements will be taken in duplicate and the mean
taken for data entry.
Venous sampling
Metabolic profile
Venous blood samples will be collected in the morning
following a 12-hour fast. Participants will be asked to
refrain from moderate-vigorous intensity exercise for
24 hours prior to collection. Samples will be taken to
measure glucose, insulin, lipid profile (total cholesterol
(TC), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and triglycerides
(TG)), glycosylated haemoglobin levels (HBA1c), C -
reactive protein (CRP), leptin, total adiponectin and sex
hormone binding globulin. Insulin resistance will be esti-
mated using the Homeostatic Model Assessment: [(Fasting
glucose (mmol.L-1) x fasting insulin (mU.L-1))/22.5] [35].
Many biomarkers of carcinogenesis must be collected
and stored prior to cancer occurrences, to ensure an
unequivocal link between biomarker exposure and
tumorgenesis [36]. Previous studies examining lifestyle
factors in this group have adopted a case-control design
and therefore have not facilitated this type of analysis. In
the current prospective study, serum and plasma samples
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for future analysis of associations between carcinogenesis
and biological markers of obesity, physical activity
and diet.
Telomere length
Peripheral blood mononuclear cells (PBMCs) will be
isolated from venous blood by density centrifugation
using Ficoll-Paque™ Plus (GE Healthcare, Uppsala,
Sweden). Genomic DNA will be extracted from PBMCs by
standard procedures. Telomere length will be measured in
extracted genomic DNA by quantative polymerase chain
reaction (qPCR) using a method adapted from the one
origanally described by Cawthon [37]. Briefly, two PCRs
will be performed for each sample: one to amplify the telo-
meric DNA and a second to amplify a single-copy control
gene (36B4, acidic ribosomal phosphoprotein PO). This
provides an internal control to normalize the starting
amount of DNA. A five-point standard curve (2-fold serial
dilutions from 10 to 0.625 ng of DNA) will be included on
all plates to allow the transformation of Ct (cycle thresh-
old) into nanograms of DNA. All samples will be run in
triplicate and the median will be used for subsequent cal-
culations. A relative measurement of the telomere length
of each sample will be calculated by dividing the amount
of telomeric DNA by the amount of control-gene DNA.
Two control samples will be run in each experiment to
allow for normalization between experiments and period-
ical reproducibility experiments will be performed to guar-
antee correct measurements.
Genomic DNA samples (50 ng) will be amplified in a
total reaction volume of 20 μl containing 2X Quantifast ™
SYBR green PCR master mix (Qiagen Inc., CA, USA), 1 μl
of forward and reverse primer (Metabion, Germany) and
7 μl of DNase free water. For the telomere amplification
PCR, 300 nM of each primer (tel1b: CGGTTTGTTTGGG
TTTGGGTTTGGGTTTGGGTTTGGGTT; tel2b: GGCT
TGCCTTACCCTTACCCTTACCCTTACCCTTACCCT)
will be used. The thermal cycling profile for the
telomere amplification will be 30 cycles of amplifica-
tion at 95°C for 15 s and at 56°C for 60 s. For the
control gene amplification, 300nM of forward primer
(36B4u: CAGCAAGTGGGAAGGTGTAATCC) and
500nM (36B4d: CCCATTCTATCATCAACGGGTACAA)
of reverse primer will be used. The thermal cycling profile
in this instance will be 35 cycles of amplification at 95°C
for 15 s and at 56°C for 20 s and 72°C for 20 s. Both
PCR reactions will require an initial denaturation step
at 95°C for 15 min. Threshold cycle (Ct) values for each
sample will be converted into nanograms of DNA using
standard curves. Ct values from the telomere assay will be
normalized to the single gene reference. The telomere
length (x) from each sample will be calculated as the telo-
mere to single copy gene ratio (T/S ratio) and will bebased on the calculation of the ΔCT [CT(telomere)/CT
(single gene)]. Telomere length (expressed as a relative
T/S ratio) will be normalized to the average T/S ratio
of the reference sample.
Metabolic syndrome classification
The metabolic syndrome will be diagnosed in the presence
of any three of the following: elevated waist circumference
(≥80 cm); elevated TG (≥1.7 mmol.L-1) or drug therapy
for lipid abnormalities; reduced HDL-C (<1.3 mmol.L-1) or
drug therapy for lipid abnormalities; elevated blood pres-
sure (systolic ≥130 mmHg and/or diastolic ≥85 mmHg) or
antihypertensive medication; elevated fasting glucose
(≥100 mg.dL-1) or glucose-lowering medication [38].
Physical activity
Current physical activity levels will be objectively
measured using the RT3 activity monitor (Stayhealthy Inc.
Montrovia, California, USA). The RT3 activity monitor is a
small, lightweight, battery operated device, designed to
measure accelerations along three orthogonal planes
(triaxial accelerometer). Participants will wear the moni-
tor for seven days, during waking hours, following each
active assessment (baseline, two-years and five-years).
Participants will be provided with the monitor following
completion of each assessment and will be given detailed
written and verbal instruction on its use. Participants will
also be provided with a stamped addressed envelope to
return the monitor to the centre after one week (battery
life of the monitor = 21 days). The validity [39] and reli-
ability [40] of the accelerometer have been established.
The output from the RT3 activity monitor will provide
objective quantification of sedentary, light, moderate and
vigorous intensity activity, while also facilitating analysis
for adherence to activity guidelines.
Physical activity during the preceding 12 months will be
estimated using two quantitative history questionnaires,
The Minnesota Leisure-Time Physical Activity Question-
naire (MLTPAQ) and the Tecumseh Occupational
Physical Activity Questionnaire (TOPAQ). The MLTPAQ
is an interview administered questionnaire, measuring
leisure-time physical activities [41] while the TOPAQ can
be either self-administered or interview based and focuses
on occupation-related activities of a maximum of three
jobs [42]. Both questionnaires measure frequency of
activity during the preceding year in terms of months and
time per occasion, and combine this information with
intensity scores to measure physical activity in terms of
metabolic-equivalent minutes per day (MET-min/day)
[41,43]. The MET-score can be derived from the Compen-
dium of Physical Activities [44], and values can be updated
accordingly during the study period. The questionnaires
will be interview-administered at each of the three active
assessment points (baseline, two-years and five-years).
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established in a range of populations [41,42,45,46], with
one study reporting significant correlations between
cardiorespiratory fitness and both leisure-time activity
and household activity in 375 middle-aged women [47].
Both the MLTPAQ and the TOPAQ will be completed
during each of the three active assessments, through inter-
view, according to standardised interview guidelines [41].
Finally, the Godin Leisure-Time Exercise Questionnaire
will be incorporated into the annual questionnaire. Partici-
pants will be required to complete this questionnaire
independently, but will be informed to contact study
personnel should issues arise. The Godin is a simple,
self-administered, four-item questionnaire that is designed
to measure an individual’s leisure-time activity during a
typical week to provide a global impression of an individ-
ual’s activity status [48]. The validity and reliability of the
questionnaire have been established [46,48] and the ques-
tionnaire has been widely used in cancer research [49,50].
Dietary intake
Dietary intake will be assessed using two different
methods, in this prospective cohort study on modifiable
risk factors for BRCA1 and BRCA2 associated breast
cancer, “current” intake will be assessed using food diaries
and “habitual” or usual intake assessed by a food fre-
quency questionnaire (FFQ).
Participants will be asked to complete an open-ended
estimated 3 day food diary following each of the three
active assessments. Participants will be provided with
the diary at the end of each assessment and receive
detailed verbal and written instructions detailing how it
should be completed. The diet-diary booklet contains
clear instructions of how to complete the food diary, as
well as a detailed good and poor example of food intake.
The instructions indicate that the respondent should
record the food brand, portion size, cooking methods
and includes a prompt for the name and daily dose of
any vitamin, mineral or food supplements taken each
day. General questions, for example, on the type of milk,
spreadable fat usually consumed, and salt use will be
asked as part of a general food habits questionnaire.
Participants will be given a prepaid envelope to return
the completed diary. The energy intake: calculated BMR
ratio [51] will be used as a measure of the degree of en-
ergy underreporting with each dietary method.
The FFQ used in this prospective study is a self-
administered Willett FFQ adapted from the European
Prospective Investigation of Cancer (EPIC) study [36] and
was used in the Irish Survey of Lifestyle, Attitudes and
Nutrition (SLÁN) 2007 [52]. This FFQ has previously
been validated for use in an Irish adult population [53].
The FFQ consists of a checklist of 149 food and beverage
items divided into the following main food groupsconsumed in Ireland; bread and savoury biscuits; cereals;
potatoes, rice and pasta; dairy products and fats, meat fish
and poultry; fruit; vegetables; sweets and snacks; soups,
sauces and spreads and lastly drinks. Participants will be
asked to report how often each food item was consumed
during the previous year using common units or portion
size for each food, e.g. one egg or one slice of bread will
be specified. The nine frequency responses range from
‘never or less than once per month’ to ‘six or more times
per day’. Calculations for nutrient intake can be estimated
via computerized software programs that multiply the
reported frequency of each food by the amount of nutrient
in a serving of that food. The FFQ will be incorporated into
the annual questionnaire and completed by participants
independently at home. Participants will be encouraged to
contact study personnel if issues arise.
Annual questionnaire
Information on cancer occurrence and potential con-
founding factors affecting breast cancer risk will be
gathered using questionnaires which will be completed on
an annual basis after participants have enrolled. The
questionnaire aims to track changes in modifiable lifestyle
risk factors (weight, smoking, alcohol use, physical activity
and diet), risk reducing procedures (prophylactic surgery),
reproductive factors (childbirth, breastfeeding, use of oral
contraceptive pill or hormonal replacement therapy) or
cancer occurrence.
Statistical analysis
Sample size calculation: There is some evidence to suggest
an association between BMI and breast cancer incidence
in BRCA mutation carriers [19-21] and even stronger
evidence to suggest an association with sporadic breast
cancer [7]. Therefore BMI was the chosen outcome on
which the power analysis is based. Assuming a difference
of in BMI of 15 kg.m-1 between cases and controls,
with a relative risk of 2.08, 80% power and two-sided
5% significance level 141 participants would be required
per group. However, a minimum sample size of 352 was
calculated to allow for a 25% drop out rate due to the long-
term nature of this study.
Data will be analysed using the SPSS package for
Windows. Baseline descriptive statistics will be
presented as means (standard deviations) for normally
distributed continuous data, medians (inter quartile
range, IQR) for non-normal data and as frequency (per-
centage) for categorical variables. Distributions will be
checked for normality using the K-S test and non-
normal data will be transformed using appropriate trans-
formations. Differences in means of continuous variables
(waist circumference, blood pressure (systolic and dia-
stolic), lipids (TC, HDL-C, LDL-C and TG), glucose, in-
sulin, HBA1c, CRP, leptin, adiponectin, BMI, fat free
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in each domain of physical activity, energy intake, telomere
length) will be compared across categories (BMI sub-
groups, presence or absence of metabolic syndrome, ad-
herence to physical activity guidelines) using independent
sample t-tests or ANOVA as appropriate for normally dis-
tributed variables and the Mann Whitney U test (or
Kruskal-Wallis test) for non-normally distributed data.
Chi-squared analysis will be used to compare categorical
variables across the above stated groups.
Pearson or Spearmans correlation analysis will be
conducted between body composition (BMI, waist
circumference, percentage body fat), physical activity
and dietary intake and the following variables: insulin
resistance, leptin, adiponectin, inflammatory markers
and telomere length for normally and non-normally
distributed data respectively. Variables found to be
associated at p<0.10 will be examined further using
separate multiple regression analyses with body com-
position, physical activity and dietary intake as the
dependent variables.
Cox proportional hazards regression models will be
used to compute adjusted hazard ratios of time to
breast cancer (event) with 95% confidence intervals.
Data will be censored at the last available follow-up
where the breast cancer status was recorded. Continu-
ous variables will be categorised into known cut-points
based on previous research (BMI will be categorised as
<18.5 kg.m-2, 18.5-24.9 kg.m-2, 25-29.5 kg.m-2, 30-34
.9 kg.m-2, 35-39.9 kg.m-2, >40 kg.m-2; waist circumfer-
ence will be categorised as <80 cm, 80-87.9 cm, >88 cm;
physical activity will be categorised as adherence to physical
activity guidelines (30 minutes moderate intensity activity,
5 days per week) and non-adherence to activity guidelines).
Quartile cut-offs will be established for markers without
pre-determined categories. Metabolic syndrome variables
(waist circumference, blood pressure, HDL-C, TG and glu-
cose) will be standardized to z-score variables with mean=0,
SD=1 and a composite z-score will be computed for
the presence/absence of the metabolic syndrome.
Confounding variables that will be considered in the
analysis include: prophylactic surgery, hormone ther-
apy use, parity, age at menarche, breastfeeding his-
tory, age at first birth, oral contraceptive use, smoking
and age. All analyses will be stratified according to
menopausal status.
Due the repeated nature of the data a multilevel
regression model will be performed to examine the re-
lationship between changes over time in outcome mea-
sures, such as body composition, physical activity and
dietary intake, and the metabolic syndrome while con-
trolling for other confounding variables. Significance
at p<0.05 will be assumed and SPSS will be used for
statistical analysis.Data collection
Participant recruitment will be co-ordinated by EG and
SMcG. Data will be collected by EG and processed by
EG, SMcG and LH. Standardized testing and data
processing protocols have been developed to ensure
long-term valid data collection methods. Long-term
management of the data collection and processing will
be directed by L.C. and JH (principle investigators). All
measurements and data processing will be completed at
the Trinity Centre for Health Sciences, St. James’s
Hospital, Dublin, Ireland.
Discussion
The results of this prospective cohort study will provide
valuable information regarding the risk reducing potential
of modifiable risk factors for breast cancer in unaffected
BRCA1 and BRCA2 gene carriers. To date, no study has
prospectively examined lifestyle risk factors in this group,
nor have the biological mechanisms linking obesity and
physical inactivity to breast cancer risk been investi-
gated. This study will provide information regarding
whether modifiable factors including body composition,
the metabolic syndrome, physical activity and dietary
intake can modulate breast cancer risk in BRCA
mutation carriers, whether risk of breast cancer occur-
rence can be predicted in these individuals by PBMC
telomere length and whether telomere length in these
individuals is associated with various physical activity and
lifestyle factors.
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